rs267607734
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000249.4(MLH1):c.306+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000249.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1419572Hom.: 0 Cov.: 25 AF XY: 0.00 AC XY: 0AN XY: 708766
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
This variant is considered pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. mRNA analysis has demonstrated abnormal mRNA splicing occurs [PMID: 12183410, 16341550]. -
Lynch syndrome 1 Pathogenic:1
- -
not provided Pathogenic:1
- -
Gastric cancer Pathogenic:1
- -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This variant has been reported in several individuals affected with Lynch syndrome (PMID: 10471527, 11151427, 15849733, 27601186). ClinVar contains an entry for this variant (Variation ID: 90142). This sequence change affects a donor splice site in intron 3 of the MLH1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MLH1 are known to be pathogenic (PMID: 15713769, 24362816). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.306+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 3 of the MLH1 gene. This mutation has been described in multiple unrelated Lynch syndrome families, including an Iranian family in which the proband was affected with colon cancer at 49 years and had a family history of colon and endometrial cancers (Planck M et al. Int. J. Cancer 1999 Oct;83(2):197-202), and a German family meeting Amsterdam Criteria, in which the proband's tumor was MSI-high (Pistorius SR et al. Int. J. Colorectal Dis. 2000 Nov;15(5-6):255-63). This alteration has also been shown to lead to aberrant splicing (Xiong HY et al. Science 2015 Jan;347(6218):1254806). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at